Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439264 | 0.84 | DRD2 (0.44) | BACE1SLC6A4 | |
| SCHEMBL2435034 | 0.84 | BACE1 (0.41) | BACE1KDM4EMAPTKMT2A | |
| SCHEMBL2434126 | 0.82 | BACE1 (0.40) | BACE1KDM4EMAPTKMT2A | |
| SCHEMBL2436185 | 0.80 | BACE1 (0.47) | BACE1 | |
| SCHEMBL2433619 | 0.80 | BACE1 (0.39) | BACE1 | |
| SCHEMBL2438161 | 0.80 | BACE1 (0.51) | BACE1 | |
| SCHEMBL2433919 | 0.80 | BACE1 (0.62) | BACE1 | |
| SCHEMBL2435756 | 0.79 | BACE1 (0.63) | BACE1 | |
| SCHEMBL2439284 | 0.78 | BACE1 (0.61) | BACE1 | |
| SCHEMBL2435070 | 0.77 | BACE1 (0.47) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | BACE1 1/4885HTR1D 2771/4885TRPM8 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.